Eli Lilly & Co. and Boehringer Ingelheim are pleased to announce that their groundbreaking drug, Jardiance, has been approved by the U.S. Food and Drug Administration (FDA) for use in adults with chronic kidney disease. Previously utilized for heart failure and diabetes, Jardiance has now been recognized as an effective treatment option for this condition.
The FDA's approval encompasses the use of Jardiance tablets to reduce the risk of sustained decline in kidney function, end-stage kidney disease, cardiovascular death, and hospitalization in adults living with chronic kidney disease. This exciting development provides a much-needed solution for a significant portion of the U.S. population.
According to data from the Centers for Disease Control and Prevention (CDC), approximately one in seven U.S. adults currently suffer from chronic kidney disease, with up to 90% of them remaining unaware of their condition. By expanding the potential applications of Jardiance, Eli Lilly & Co. and Boehringer Ingelheim aim to improve diagnosis rates and enhance patient outcomes across the nation.
Jardiance's inclusion among the first 10 drugs selected for initial round Medicare price negotiations under the Inflation Reduction Act further highlights its significance within the pharmaceutical industry. This achievement underscores its effectiveness and potential to transform patient care and management.
Eli Lilly & Co.'s stock has experienced positive growth, with a 0.3% increase in premarket trading on Friday alone. Overall, the company's shares have risen by an impressive 50% year-to-date, exceeding market expectations. Meanwhile, the S&P 500 index has achieved a 12.8% gain during the same period.
As Jardiance receives FDA approval for its expanded use in chronic kidney disease, Eli Lilly & Co., alongside Boehringer Ingelheim, anticipates providing a revolutionary treatment option that will significantly improve the lives of countless adults suffering from this condition.
